Infection as Complication of Medical CareAIRNCT01499927
Early Reassessment of Intravenous Antiinfective Therapy Due to "Antiinfective Reminders" (AIR Study)
A study testing electronic reminders in people with Infection as Complication of Medical Care, run by University of Zurich at 1 site in Switzerland.
Trial summary
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Infection as Complication of Medical Care
- What is being tested?
- electronic reminders
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 74,766 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jan 2012to Dec 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- all in-patients in treatment with an intravenous antiinfective for >60h,
- hospitalized in a ward with computerized physician order entry (cpoe)
Who cannot join
- outpatients,
- ward without cpoe,
- no intravenous antiinfective treatment
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich, Center for Clinical Research
Zurich, Canton of Zurich, 8091
About this study
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.
Read the detailed description
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.
- Being tested
- electronic reminders
- Keywords
- Early reassessment of intravenous antiinfective therapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
electronic remindersOther
Also called computerized decision support
Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
| Study group | Role | What they receive |
|---|---|---|
| electronic reminders | Active comparator | Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders Receives: Other: electronic reminders |
| no electronic reminders | No intervention | Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support |
What is being measured
The primary outcome is the main question the study is designed to answer.
duration of intravenous antiinfective therapy until switching
Measured: 1 year
Secondary outcomes (5)
costs (per year, per day and patient)
Measured: 1 year
defined daily doses (per 100 days)
Measured: 1 year
duration of hospitalization
Measured: 1 year
ratio of narrow to broad-spectrum antibiotics
Measured: 1 year
requests for consultations
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2011 (estimated)
- Study startJan 2012
- Primary completionDec 2012
- Study completionDec 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Infection as Complication of Medical CareStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 74,766 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Juerg Blaser, Professor, Principal investigator, University Hospital Zurich, Center for Clinical Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01499927
- Sponsor's protocol ID
- FZMI-KEK-ZH-Nr. 2010-0457
- Acronym
- AIR
- Status last verified
- Dec 2013
- First submitted
- 15 Nov 2011
- Last updated
- 19 Dec 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Beeler PE, Kuster SP, Eschmann E, Weber R, Blaser J. Earlier switching from intravenous to oral antibiotics owing to electronic reminders. Int J Antimicrob Agents. 2015 Oct;46(4):428-33. doi: 10.1016/j.ijantimicag.2015.06.013. Epub 2015 Jul 21.
PubMed 26293470
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Reassessment of Intravenous Antiinfective Therapy Due to "Antiinfective Reminders" (AIR Study)
- ClinicalTrials.gov ID
- NCT01499927
- Acronym / sponsor ID
- AIR / FZMI-KEK-ZH-Nr. 2010-0457
- Keywords
- Early reassessment of intravenous antiinfective therapy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 74,766 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- Jan 2012
- Primary completion
- Dec 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 26 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs and risk of complications. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.
Detailed description
Switching from intravenous application of antiinfective agents to oral therapy is often performed late including high costs, risk of complications as well as higher workload on nursing. This study will investigate the impact of displayed reminders in the electronic patient chart after 60h of intravenous therapy with an antiinfective agent.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| electronic reminders | Active comparator | Other: electronic remindersBehavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders |
| no electronic reminders | No intervention | –Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- all in-patients in treatment with an intravenous antiinfective for >60h,
- hospitalized in a ward with computerized physician order entry (cpoe)
Key exclusion criteria (3 listed)
- outpatients,
- ward without cpoe,
- no intravenous antiinfective treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| electronic remindersAlso: computerized decision supportBehavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders | Other | electronic reminders |
Primary outcome
duration of intravenous antiinfective therapy until switching
Time frame: 1 year
5 secondary outcomes
costs (per year, per day and patient)
Time frame: 1 year
defined daily doses (per 100 days)
Time frame: 1 year
duration of hospitalization
Time frame: 1 year
ratio of narrow to broad-spectrum antibiotics
Time frame: 1 year
requests for consultations
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2013.
- Derived from this study: PubMed 26293470Beeler PE, Kuster SP, Eschmann E, Weber R, Blaser J. Earlier switching from intravenous to oral antibiotics owing to electronic reminders. Int J Antimicrob Agents. 2015 Oct;46(4):428-33. doi: 10.1016/j.ijantimicag.2015.06.013. Epub 2015 Jul 21.
Related trials for Infection as Complication of Medical Care
RecruitingObservational study
Swiss Revision Cohort
Joint (Knee or Hip Replacement), Infection as Complication of Medical Care
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juerg Blaser, Professor principal investigator
University Hospital Zurich, Center for Clinical Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing electronic reminders in people with Infection as Complication of Medical Care, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
duration of intravenous antiinfective therapy until switching (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01499927, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2013.